My SciELO
Services on Demand
Article
Indicators
Cited by SciELO
Related links
Similars in SciELO
Share
Revista Cubana de Química
On-line version ISSN 2224-5421
Abstract
GUERRERO-PORRAS, Gabriel Rafael; SABLON-CARRAZANA, Marquiza; DIAZ-GARCIA, Alicia M. and RODRIGUEZ-TANTY, Chryslaine. Gd2O3 nanoparticles grafted to Amylovis®-204, with potential affinity for β-amyloid plaques. Part II. Rev Cub Quim [online]. 2023, vol.35, n.1, pp. 29-45. Epub Jan 17, 2023. ISSN 2224-5421.
For Magnetic Resonance Imaging (MRI) visualization of molecular markers —β-amyloid peptide (βA)— of Alzheimer's disease, the use of contrast agents (CAs) is necessary. In clinical practice, obtaining gadolinium(III) oxide nanoparticles (Gd2O3NPs) as ACs is a very active field of research. In this work, one of the Amylovis® compounds, naphthalene derivatives obtained at CNEURO with high affinity for βA, was conjugated to Gd2O3NPs. The Gd2O3NPs were characterized by FT-IR, TEM, TGA, DLS and ζ-potential. By FT-IR and TEM, respectively, the functionalization with carboxyl groups and the size of the Gd2O3NPs (< 10 nm) were corroborated. Although the amount of Amylovis®-204 conjugated could decrease the colloidal stability of Gd2O3NPs, the values of hydrodynamic diameters (< 200 nm) and longitudinal relaxivity of Gd2O3NPs justify their potential use as AC for the proposed purpose.
Keywords : gadolinium(III) oxide nanoparticles; MRI contrast agent; Amylovis®; Alzheimer’s disease..